Core Viewpoint - The article highlights the health risks associated with consuming raw or undercooked crabs, particularly the potential for lung fluke infection, which can lead to serious health issues [1][2]. Summary by Sections What is Lung Fluke Disease? - Lung fluke disease, also known as paragonimiasis, is caused by the lung fluke parasite, which requires two intermediate hosts for its development: freshwater snails and freshwater crabs or other crustaceans [2]. - The lifecycle involves the eggs hatching in water, infecting snails, and then transferring to crabs, where they develop into infectious larvae that can infect humans when consumed raw or undercooked [2]. Symptoms of Lung Fluke Disease - Symptoms vary based on the number of parasites, the infected organs, and the individual's immune response [3]. - Acute symptoms may include fever, fatigue, loss of appetite, abdominal pain, and diarrhea, which can be easily overlooked [3]. - Severe cases can lead to allergic reactions, high fever, chest pain, cough, and potential organ damage, with chronic symptoms being more complex and organ-specific [3]. Diagnosis - Diagnosis relies on epidemiological history, clinical symptoms, laboratory tests, and imaging studies [4]. - The gold standard for diagnosis is finding lung fluke eggs in sputum or feces, with blood tests and imaging aiding in the diagnosis [4]. Prevention - Prevention focuses on avoiding the consumption of raw or undercooked crabs and other freshwater crustaceans [5]. - It is essential to ensure thorough cooking of crabs and to maintain food hygiene to prevent cross-contamination [5].

Core Viewpoint - The company, Jindawei (002626.SZ), announced that its subsidiary, Jiangsu Chengxin Pharmaceutical Co., Ltd., has received a veterinary drug approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the product Pyrantel, with the approval number 102091173 [1] Group 1 - The approval signifies a regulatory milestone for the company in the veterinary pharmaceutical sector [1] - The product Pyrantel is expected to enhance the company's product portfolio and market presence in the veterinary medicine industry [1]

Core Viewpoint - The company Jindawei (002626) announced that its subsidiary Jiangsu Chengxin Pharmaceutical Co., Ltd. has received the veterinary drug approval number from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the product with the generic name Praziquantel [1] Company Summary - Jindawei's subsidiary Jiangsu Chengxin Pharmaceutical has obtained a significant regulatory approval, which may enhance its product portfolio and market presence in the veterinary drug sector [1]

Group 1: Company Overview - The company primarily engages in the research, production, and sales of nutritional health foods (including raw materials and finished products) and feed additives [2][3] - The production of health food raw materials and feed additives mainly occurs domestically, with a high export ratio; finished health food products are primarily produced and sold overseas, showing significant growth through cross-border e-commerce [3] Group 2: Product Development and Market Position - The company utilizes synthetic biology as a foundational technology for large-scale production of various raw materials, including Coenzyme Q10, NMN, NADH, Vitamin K2, and others [3] - Coenzyme Q10 holds the largest global market share, demonstrating notable cost and scale advantages [3] - The company aims to reduce production costs for products like astaxanthin, DHA, and EPA to enhance market competitiveness [3] Group 3: Brand and Sales Strategy - The company owns two major health food brands, Doctor's Best and Zipfizz, with production capabilities for capsules, tablets, and powders [3][4] - Doctor's Best is a well-known health brand in North America, showing steady growth, while Zipfizz maintains stable performance with new products developed for the U.S. market [4] - The marketing strategy for domestic health food business focuses on market insights, product strategy, resource integration, and data-driven upgrades to create market-leading products [4] Group 4: Financial Performance - The company's performance growth in the first half of 2025 is primarily attributed to increased sales of Coenzyme Q10, vitamins, and domestic health products [3]